LUPIN LIMITED

In 2024, India's CDSCO approved 19 new drugs, including next-gen therapies for chronic diseases by global majors. Eli Lilly's Mounjaro for diabetes/obesity, Orchid Pharma's Enmetazobactam for resistant bacteria, Cipla's plazomicin for UTIs, Sun Pharma's Etifoxine for anxiety, Dr Reddy's Elobixibat for constipation, and Zydus/Lupin's Vonoprazan for stomach ulcers were notable. New cancer drugs like Eli Lilly's Retevmo and Zydus's nelarabine were also approved.

Asia Deal Watch: Kaken acquires Aadi subsidiary and cancer drug Fyarro. Other deals include Hangzhou DAC/Aadi, Astellas/Sangamo, Kyorin/Bayer, Eisai/Newron, Lupin/Boehringer Ingelheim, Asahi Kasei/Chiome.

Lupin Limited received FDA approval for its emtricitabine and tenofovir alafenamide tablets, 200 mg/25 mg, a generic equivalent of Gilead Sciences' Descovy, eligible for 180 days of shared generic exclusivity. The product, manufactured at Lupin's Nagpur facility, is indicated for HIV-1 treatment and PrEP. Descovy had annual US sales of USD 3,556 million.

Lupin receives U.S. FDA approval for its generic Emtricitabine and Tenofovir Alafenamide Tablets, eligible for 180-day exclusivity, indicated for HIV-1 treatment and PrEP. Annual sales of the branded version were USD 3,556 million in the U.S.

Biocon's biosimilar breakthrough, Reliance's stake acquisition, Lupin's diabetes portfolio expansion, JK Paper's consolidation, Aurobindo's EMA approval, and JSW Energy's legal action.

Zinka Logistics Q2 loss widens, revenue surges. Biocon's subsidiary gets CHMP positive opinion for biosimilar. Reliance Industries acquires 74% stake in NMIIA. GMM Pfaudler appoints new CFO, closes Hyderabad facility. GE Power India gets order extension. 63 Moons approves Rs 1,950 crore OTS. Afcons Infrastructure wins Bhopal Metro Rail project. Godrej Agrovet gets land for oil palm expansion. Aurobindo Pharma's subsidiary gets CHMP positive opinion for biosimilar. JSW Energy files petition for invoice recovery. Bharat Forge's subsidiary invests in Edgelab. JK Paper consolidates subsidiaries, acquires stake in Radhesham Wellpack. Jaiprakash Power Ventures gets stay on Rs 1,334 crore demand. Max Financial Services changes Max Life name to Axis Max Life Insurance. Lupin acquires diabetes trademarks. Premier Explosives partners with Global Munition for defense products. Navin Fluorine CEO resigns. Aeroflex Industries approves Rs 400 crore QIP. Hero Motocorp sponsors Hockey India League. PVR INOX opens multiplex in Dehradun.

Nifty traders faced volatility on December 13, with a sharp recovery from early losses. The Nifty surged nearly 600 points from its lows, reviving hopes for higher levels. Key resistance is at 24,857, with potential to reach 25,000. The upcoming week's focus is on the US Federal Reserve's policy decision, expected to influence market direction.

Reliance Industries acquired a 74% stake in Navi Mumbai IIA for ₹1,628 crore. Biocon's biosimilar YESINTEK received EMA approval. Aurobindo Pharma's biosimilar Zefylti got a positive EMA opinion. Bharat Forge invested €2.5 million in Edgelab S.p.A. Lupin acquired three anti-diabetes trademarks from Boehringer Ingelheim. Aeroflex Industries plans to raise ₹400 crore via QIP. Afcons Infrastructure secured a ₹1,007 crore metro rail contract. HBL Power Systems received a ₹1,522.4 crore order for Train Collision Avoidance Systems. RITES won a ₹297.67 crore project for an Integrated Check Post. 63 Moons Technologies approved a ₹1,950 crore settlement by NSEL Investors Forum.

Eli Lilly plans to introduce Tirzepatide, marketed as Mounjaro, to India in 2025, targeting type 2 diabetes and obesity. The move aligns with the company's strategy to expand its portfolio in India, considering local affordability and value. Eli Lilly has been operating in India since 1993, collaborating with local firms for its diabetes portfolio, and aims to address India's growing healthcare challenges.

Lupin receives USFDA tentative approval for Abacavir, Dolutegravir, and Lamivudine tablets for oral suspension, a once-daily regimen for treating HIV-1 in pediatric patients.